

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

19 Jun 2026

### Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit

#### Protocol summary

##### Study aim

The effect of supplementation with vitamins A, D, E, C, B on disease severity and mortality in patients with COVID-19

##### Design

A randomized, double-blind, placebo-controlled clinical trial

##### Settings and conduct

Only patients are unaware of the placement in the intervention or control group. Location: The intensive care unit is located at Imam Khomeini Hospital.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria : 1- Between 20 and 60 years old 2. Both men and women 3. The definitive or clinical diagnosis of COVID-19 4. Satisfaction with the study collaboration 5.BMI: 18.5-30 6. COVID-19 treatment protocol is almost identical in both groups 7- Patients not participating in other trials 8- No liver and kidney disorders Non-Entry Criteria: - Patients with rare and specific viral diseases such as HIV - Patients undergoing chemotherapy over the past month - Any other condition that the specialist diagnoses is very specific.

##### Intervention groups

Patients were divided into intervention and control groups. Intervention group supplemented with vitamin D at 25,000 international units of vitamin A daily, 600,000 international units of vitamin D once daily, 300 units of vitamin E twice daily, 500 mg Vitamin C is taken 4 times a day and finally B vitamins are taken as a daily solute ampoule. The control group received no supplement or placebo.

##### Main outcome variables

Variables: 1- Weight, height and BMI of patients 2. Severity of pulmonary involvement according to CT scan 3. Respiratory support (Invasive or Non-Invasive) 4% oxygen saturation 5- Serum levels of WBC, CRP, IL6, TNF- $\alpha$ , IFN-G, ESR 6. The patient's body temperature 7. The presence or absence of involvement of other organs 8- Duration of hospitalization 9. Mortality

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20200319046819N1**

Registration date: **2020-04-04, 1399/01/16**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-04-04, 1399/01/16**

Update count: **0**

##### Registration date

2020-04-04, 1399/01/16

##### Registrant information

##### Name

Sama Bitarafan

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 6694 8899

##### Email address

bitarafans@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-04-02, 1399/01/14

##### Expected recruitment end date

2020-07-04, 1399/04/14

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Impact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unit

## Public title

supplementation in COVID-19

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Age between 20 and 60 years Both males and females  
COVID-19 clinical or definitive diagnosis Satisfaction with the study patient do not participate in other trial designs  
BMI: 18.5-30 - Lack of renal and hepatic abnormalities

### Exclusion criteria:

Patients with specific and rare viral diseases such as HIV etc. Patients have been undergoing chemotherapy for the past month Any other patients that the specialist knows to be unique.

## Age

From **20 years** old to **60 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Participant

## Sample size

Target sample size: **60**

## Randomization (investigator's opinion)

Randomized

## Randomization description

blocking randomization

## Blinding (investigator's opinion)

Single blinded

## Blinding description

Patients are unaware of being placed in the intervention or control group after declaration of consent. All treatment staff are aware of the patients in which group due to the specific conditions of the ICU and the absence of placebo for control group.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

National Committee on Ethics in Tehran university of medical sciences

##### Street address

Block A, Central Headquarters of Ministry of Health

and Medical Education, Iran Sima Street, between South Flamak and Zarafshan, Qods Town (West), Tehran,

## City

Tehran

## Province

Tehran

## Postal code

1419733141

## Approval date

2020-04-01, 1399/01/13

## Ethics committee reference number

IR.TUMS.VCR.REC.1399.090

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19

#### ICD-10 code

U07.1

#### ICD-10 code description

COVID-19

## Primary outcomes

### 1

#### Description

WBC, CRP, IL6, TNF- $\alpha$ , IFN-G, ESR

#### Timepoint

Before and after intervention

#### Method of measurement

Laboratory blood test

### 2

#### Description

Intensity of pulmonary involvement

#### Timepoint

Before and after intervention

#### Method of measurement

CT scan

### 3

#### Description

Mortality

#### Timepoint

Before and after intervention

#### Method of measurement

Observation

## Secondary outcomes

### 1

#### Description

Body Mass Index

#### Timepoint

Before and after intervention

## Method of measurement

Measuring weight and height and using the formula

## 2

### Description

Duration of hospitalization

### Timepoint

Before and after intervention

### Method of measurement

Observation

## 3

### Description

Saturation percentage of blood oxygen

### Timepoint

Before and after intervention

### Method of measurement

Oxymeter

## Intervention groups

## 1

### Description

Intervention group: Vitamin supplementation in order (ampoules): 25,000 international units of vitamin A daily, 600,000 international units of vitamin D once during the intervention time, 300 international units of vitamin E, 2 times a day, 500 mg of vitamin C, 4 times a day and B vitamins in the form of one Soluvit ampoule in a day. The control group does not receive any supplement or placebo. In this study, the duration of supplementation and evaluation of patients is one week .Except for Soluvit (Fresenius Kabi New Zealand) , all supplements are made in Iran. Soluvit: Thiamine nitrate 3.1 mg, Sodiumriboflavine phosphate 4.9 mg(corresponding to Vitamin B2 3.6mg), Nicotinamide 40 mg,Pyridoxine hydrochloride 4.9 mg(corresponding to Vitamin B6 4.0mg), Sodium pantothenate 16.5 mg(corresponding to Pantothenic acid15 mg), Sodium ascorbate 113 mg(corresponding to Vitamin C 100mg), Biotin 60 µg, Folic acid 400 µg,Cyanocobalamin 5 µg,

### Category

Treatment - Drugs

## 2

### Description

Control group: no placebo

### Category

Treatment - Drugs

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

Imam Khomeini Hospital, Intensive Care Unit

#### Full name of responsible person

Sama Bitarafan

### Street address

Intensive Care Unit of open heart, Imam Khomeini Hospital, Keshavarz Blvd, Tehran

### City

Tehran

### Province

Tehran

### Postal code

1419733141

### Phone

+98 21 6694 8899

### Fax

+98 21 6658 1558

### Email

Bitarafans@gmail.com

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Tehran University of Medical Sciences

#### Full name of responsible person

Dr. Mohammad Ali Sahraian

#### Street address

central university building, corner of Quds Street, Keshavarz Boulevard, Tehran

#### City

Tehran

#### Province

Tehran

#### Postal code

1417653761

#### Phone

+98 21 8163 4208

#### Email

rcco@tums.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Tehran University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Tehran University of Medical Sciences

**Full name of responsible person**

Sama Bitarafan

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Floor 4, Iranian Center of Neurological Research  
biulding, Imam Khomeini Hospital, Keshavarz Blvd,  
Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1419733141

**Phone**

+98 21 6694 8899

**Email**

Bitarafans@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sama Bitarafan

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Floor 4, Iranian Center of Neurological Research  
biulding, Imam Khomeini Hospital, Keshavarz Blvd,  
Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1419733141

**Phone**

+98 21 6694 8899

**Email**

Bitarafans@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sama Bitarafan

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Floor 4, Iranian Center of Neurological Research  
biulding, Imam Khomeini Hospital, Keshavarz Blvd,  
Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1419733141

**Phone**

+98 21 6694 8899

**Fax**

**Email**

bitarafans@gmail.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to  
make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to  
make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to  
make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to  
make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to  
make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable